# A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period

> **NCT05002933** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 570 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin glargine 300 U/ml

## Key facts

- **NCT ID:** NCT05002933
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-20
- **Primary completion:** 2023-02-24
- **Final completion:** 2023-02-24
- **Target enrollment:** 570 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05002933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05002933, "A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05002933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*